Flecainide toxicity is a potentially fatal condition in which this commonly prescribed heart rhythm drug overwhelms the body’s ability to handle it, causing dangerous cardiac conduction slowing, life-threatening arrhythmias, and sometimes cardiovascular collapse. Because flecainide has a narrow therapeutic window, the margin between a dose that controls an irregular heartbeat and one that poisons the heart is uncomfortably thin. The drug’s troubled history, its distinctive electrocardiographic fingerprints, and the aggressive treatments required when things go wrong make this a topic that matters to patients, caregivers, and clinicians alike.
How Flecainide Works and Why It Can Turn Dangerous
Flecainide belongs to a family of drugs called Class IC antiarrhythmics. Its job is to block sodium channels in heart cells, which slows the speed at which electrical signals travel through cardiac tissue. In a controlled setting, that slowing helps restore a normal rhythm in conditions like atrial fibrillation. The problem is that the same sodium-channel blockade can become excessive, and when it does, the heart’s electrical system grinds to a crawl.
Research on cardiac tissue shows that flecainide enters the sodium channel when it opens and then gets physically trapped inside once the channel closes again. This trapping means the drug-affected channels recover very slowly, especially at faster heart rates or more negative resting voltages.
1PubMed Central. State-dependent trapping of flecainide in the cardiac sodium channelThe result is a use-dependent block: the faster the heart tries to beat, the more channels remain blocked, and the worse the conduction slowing becomes. This is a vicious cycle in overdose situations, where the heart may try to compensate for falling blood pressure by beating faster, only to drive itself deeper into toxicity.
Sodium levels in the blood also matter. Experimental work in canine heart fibers found that raising the concentration of sodium outside the cell counteracted flecainide’s depressant effects, while lowering it made the blockade worse.2PubMed. Modulation of flecainide’s cardiac sodium channel blocking actions by extracellular sodium: a possible cellular mechanism for the action of sodium salts in flecainide cardiotoxicity This observation is the scientific basis for the main antidote used in flecainide poisoning, which we will get to shortly.
What Flecainide Toxicity Looks Like
The hallmark of flecainide toxicity is a dramatically widened QRS complex on the electrocardiogram. In normal conditions, the QRS lasts under 120 milliseconds and represents the time it takes for the electrical signal to spread across the ventricles. In severe flecainide poisoning, QRS durations can stretch beyond 200 milliseconds, sometimes doubling or tripling the normal width. The heart tracing essentially shows electrical signals crawling through cardiac tissue instead of racing efficiently.
A systematic review of published flecainide toxicity cases found that the ECG pattern varies depending on how wide the QRS has become. When it stays at or under 200 milliseconds, patients tend to show a right bundle branch block pattern with visible P waves. Once the QRS exceeds 200 milliseconds, the pattern often shifts to a left bundle branch block morphology, P waves disappear, the electrical axis swings to an abnormal northwest direction, and the QT interval lengthens.3PubMed. Flecainide Toxicity: A Case Report and Systematic Review of its Electrocardiographic Patterns and Management These wider, more chaotic patterns tend to accompany worse hemodynamic instability.
Beyond QRS widening, case series have documented PR intervals stretching to nearly half a second, sinus bradycardia down to rates in the low 40s, and various degrees of atrioventricular block.4Indian Pacing and Electrophysiology Journal. An electrocardiographic series of flecainide toxicity The drug slows conduction everywhere: through the atria, through the conduction system connecting atria to ventricles, and through the ventricles themselves. Underlying sinus node problems that were previously silent can become unmasked.
Outside the heart, symptoms of toxicity include nausea, vomiting, seizures, and in severe cases, coma.5EP Lab Digest. Acute Flecainide Toxicity: A Case Report The cardiac symptoms range from palpitations and lightheadedness to frank cardiac arrest. In the worst overdoses, the heart can lose its ability to pump effectively, leading to cardiogenic shock.
The Brugada Pattern Trap
One of the more treacherous features of flecainide toxicity is its ability to produce an ECG pattern that looks like a heart attack or Brugada syndrome. Brugada syndrome is a genetic condition associated with sudden cardiac death that creates a distinctive coved-type ST-segment elevation in the right-sided chest leads. Flecainide toxicity can produce an identical pattern on the ECG even in people who have never shown any sign of Brugada before.
Reports have described elderly patients presenting with this pattern after flecainide overdose, where clinicians initially suspected a major heart attack.6PubMed Central. Brugada pattern masquerading as ST-segment elevation myocardial infarction in flecainide toxicity A case in a pediatric patient documented the same coved-type ST elevation in the right precordial leads, along with PR prolongation, directly attributable to the drug’s sodium channel blockade.7PubMed Central. Autolytic attempt mimicking Brugada type 1 electrocardiogram pattern due to flecainide toxicity. A case report
The practical danger here is misdiagnosis. If an emergency team interprets the ECG as a STEMI and rushes the patient to the catheterization lab for a coronary intervention, they waste precious time and expose the patient to unnecessary procedures while the actual problem goes untreated. Recognizing the medication history and the broader ECG context, including the extreme QRS widening that accompanies flecainide toxicity, is critical to avoiding this mistake.
Who Is Most Vulnerable
Flecainide is cleared from the body primarily through liver metabolism and partly through the kidneys. Anything that impairs either pathway raises the risk. A study examining risk factors for toxicity in clinical practice found that chronic kidney disease, liver cirrhosis, drug interactions, and a baseline slow heart rate were all independently associated with developing toxicity.8PubMed Central. Risk Factors and Markers for Flecainide Toxicity in Clinical Practice
On the metabolism side, the liver enzymes CYP2D6 and CYP1A2 handle the bulk of flecainide breakdown.9PubMed Central. Wide Spectrum of Flecainide Toxicity: A Case Report and Literature Review Drugs that compete for the same enzymes can cause flecainide to accumulate. Common culprits include certain antidepressants, other heart medications, and some antifungal agents. Even grapefruit juice, which interferes with related liver enzymes, has been flagged as a concern.
Genetics also play a role. People inherit different versions of the CYP2D6 gene, and about 5 to 10 percent of people of European descent are poor metabolizers who break down CYP2D6 substrates much more slowly. A cohort study of patients with atrial fibrillation found that intermediate metabolizers and normal metabolizers had essentially identical outcomes when treated with a standard 100 mg twice-daily dose. However, poor metabolizers showed a notably lower event rate during the first six months of treatment, and when follow-up extended to a full year, this difference became statistically significant.10PubMed. Relevance of CYP2D6 in the Efficacy and Toxicity of Flecainide in Patients With Atrial Fibrillation: A Cohort Study This might sound like good news for poor metabolizers at first glance, but the interpretation is nuanced: the drug lingers longer, which can mean better rhythm control at standard doses but also higher risk of accumulation if the dose is not carefully managed.
Kidney disease deserves special emphasis. Even without a deliberate overdose, patients with declining kidney function can gradually accumulate flecainide to toxic levels over days or weeks. The onset can be insidious, with progressive QRS widening that nobody notices until the patient collapses. Renal impairment combined with drug interactions makes this scenario more likely.11PubMed Central. Early Recognition and Management of Flecainide Toxicity: A Case Report and Literature Review
Sodium Bicarbonate as the First-Line Antidote
The primary rescue therapy for flecainide toxicity is intravenous sodium bicarbonate. This works through two complementary mechanisms: it delivers a large bolus of sodium ions that compete with flecainide for access to the sodium channel, and it alkalinizes the blood, which helps dislodge the drug from its binding site. In canine Purkinje fiber experiments, both the increased sodium concentration and the rise in pH contributed to reversing flecainide’s effects, likely through a combination of competitive inhibition and electrostatic repulsion.12PubMed Central. Management of life-threatening flecainide overdose: A case report and review of the literature
The clinical response to sodium bicarbonate can be dramatic. Reports describe patients whose enormously wide QRS complexes narrowed immediately after an infusion began.13Journal of Emergency Medicine. Severe flecainide overdose This therapy alone has pulled patients back from the edge even in severe overdose. The approach is typically to give repeated boluses until the QRS narrows, sometimes followed by a continuous infusion to prevent relapse as the drug continues to be absorbed or redistributed.
There is a practical ceiling, though. You can only push so much sodium bicarbonate before the blood becomes dangerously alkaline or the sodium level climbs too high, creating its own set of problems. In cases where bicarbonate alone is not enough, additional therapies enter the picture.
Lipid Emulsion Therapy
Intravenous lipid emulsion, originally developed as a nutritional supplement for patients who cannot eat, has found a second life as a rescue treatment for poisoning by fat-soluble drugs. Flecainide is lipophilic, meaning it dissolves readily in fat, and lipid emulsion is thought to act as a “lipid sink” that pulls the drug out of cardiac tissue and into the bloodstream where it can be metabolized.
A case report of life-threatening flecainide overdose with severe hemodynamic collapse described successful treatment with intravenous fat emulsion when the patient was not responding adequately to other measures.14PubMed. A life-threatening flecainide overdose treated with intravenous fat emulsion The evidence base is primarily composed of case reports and series rather than controlled trials, which is inevitable since you cannot ethically run a randomized trial on poisoned patients. Still, the therapy is now widely recognized as a reasonable adjunct when sodium bicarbonate is insufficient.
A compelling pediatric example involved two brothers, aged 2 and 4, who presented two years apart with severe flecainide toxicity after accidental ingestion. Both were treated with a combination of sodium bicarbonate and 20% intravenous lipid emulsion, along with careful electrolyte management. Both recovered fully without needing mechanical circulatory support.15PubMed Central. Flecainide Toxicity Secondary to Accidental Overdose: A Pediatric Case Report of Two Brothers The authors noted that avoiding agitation-induced tachycardia, which would worsen use-dependent sodium channel blockade, may have also contributed to the positive outcome.
When the Heart Needs Mechanical Support
In the most severe cases, neither sodium bicarbonate nor lipid emulsion is enough to keep the patient alive. When the heart simply cannot pump effectively against the drug’s overwhelming sodium channel blockade, mechanical circulatory support becomes the last resort. The most commonly reported form of this is veno-arterial extracorporeal membrane oxygenation, or VA-ECMO, which essentially takes over the work of the heart and lungs by pumping and oxygenating blood outside the body.
A case report of an adolescent with fulminant flecainide intoxication who developed progressive cardiogenic shock despite medical therapy described emergency VA-ECMO cannulation. Once mechanical support was initiated, the patient’s circulation stabilized, buying time for the body to clear the drug.16BMJ Case Reports. Fulminant flecainide intoxication in an adolescent: cardiogenic shock requiring VA-ECMO support The key insight from this and similar cases is that flecainide’s effects are reversible if the patient can be kept alive long enough. The drug will eventually be metabolized, and the sodium channels will recover. ECMO bridges the gap between collapse and recovery.
One treatment that does not work well is dialysis. Flecainide distributes widely into body tissues rather than staying concentrated in the blood, which makes it a poor candidate for removal by conventional hemodialysis.17HeartRhythm Case Reports. Flecainide toxicity in renal tubular acidosis type IV treated with extracorporeal membrane oxygenation The drug is essentially hiding in fat and muscle where dialysis cannot reach it. This is a frustrating limitation, especially in patients with kidney failure who are already accumulating the drug because they cannot excrete it normally.
The CAST Trial and Why Flecainide Carries a Black Box Warning
Flecainide’s reputation as a dangerous drug dates back to the late 1980s, when one of the most important clinical trials in cardiology history was stopped early because of excess deaths. The Cardiac Arrhythmia Suppression Trial (CAST) enrolled patients who had survived a heart attack and had extra heartbeats that doctors at the time believed should be suppressed. The hypothesis was straightforward: since these extra beats predicted sudden death, eliminating them with drugs should save lives.
The preliminary results, published in 1989, showed the opposite. Patients randomized to receive encainide or flecainide had a rate of death from arrhythmia roughly 3.6 times higher than those given placebo, and overall mortality was about 2.5 times higher.18PubMed. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction The trial was halted, and the findings sent shockwaves through cardiology. The full results confirmed the pattern: over an average of ten months, 43 patients on the drugs died from arrhythmia compared to 16 on placebo.19PubMed. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial
CAST fundamentally changed how flecainide is prescribed. The drug now carries strict contraindications in patients with structural heart disease, prior heart attack, or reduced heart function. When it is used today, primarily for atrial fibrillation in patients with structurally normal hearts, the safety profile is considerably better. But the lesson of CAST looms over every prescription: in the wrong patient, flecainide does not just fail to help, it actively kills.
Flecainide Versus Propafenone
Propafenone is the other Class IC drug commonly used for atrial fibrillation, and patients often wonder how the two compare in terms of safety. Head-to-head studies suggest they are roughly equivalent in effectiveness. An Italian study following patients for twelve months found a probability of safe and effective treatment of about 77% for flecainide and 75% for propafenone, with no statistically significant difference in safety.20PubMed. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation
Where the drugs differ is in their side-effect profiles. One comparative trial noted that propafenone caused more gastrointestinal complaints, while flecainide was more likely to produce neurological side effects. Overall, more propafenone patients dropped out due to side effects, giving flecainide a slight edge in tolerability over a year of follow-up.21PubMed. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter Proarrhythmic events were rare with both drugs in patients without structural heart disease. The risk calculus changes dramatically, of course, if either drug is given to patients with underlying cardiac abnormalities.
Pediatric and Fetal Considerations
Flecainide is used in pediatric cardiology to manage supraventricular tachycardias, including in fetuses with dangerously fast heart rhythms detected during pregnancy. The drug crosses the placenta, which is actually the therapeutic intent when treating fetal arrhythmias: the mother takes the medication, and it reaches the baby through the shared blood supply. But this same feature makes dosing tricky, because there is no way to directly measure drug levels in the fetal blood.
Clinicians typically rely on maternal blood levels and the width of the QRS complex on the mother’s ECG to estimate whether the fetus is getting an appropriate amount. The drug’s narrow therapeutic index makes this a high-stakes guessing game.22PubMed Central. Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia Pharmacogenetic testing of the mother’s CYP2D6 status can help predict whether she is likely to metabolize the drug normally or accumulate it, but this is still an emerging practice rather than standard care in most centers.
Accidental pediatric ingestion is a separate and particularly frightening scenario. Young children who get into a parent’s or grandparent’s medication can develop toxicity rapidly. Clinical signs in children include lethargy, a slowed heart rate, altered consciousness, and ventricular arrhythmias.23Progress in Pediatric Cardiology. It is a fine line with flecainide: A case of flecainide toxicity in a pediatric patient The treatment approach mirrors what is done in adults: sodium bicarbonate first, lipid emulsion as an adjunct, and mechanical support if the heart cannot maintain circulation. The cases of the two brothers who both survived accidental ingestions suggest that aggressive multimodal treatment can work even without ECMO, though the decision about when to escalate to mechanical support remains a judgment call made in real time.24PubMed Central. Flecainide Toxicity Secondary to Accidental Overdose: A Pediatric Case Report of Two Brothers
Safe Prescribing and Monitoring
Given everything above, the obvious question is how to use flecainide without poisoning yourself. The current approach rests on several pillars. Before starting the drug, patients should have an echocardiogram to confirm their heart structure is normal, an ECG to check baseline conduction intervals, and kidney and liver function tests. Any structural heart disease, prior heart attack, or significant conduction delay is typically a reason to choose a different drug.
Once the drug is started, most guidelines call for in-hospital monitoring during the initial doses, with serial ECGs to watch for QRS widening. A widening of more than about 25% over baseline is usually considered a red flag that the dose is too high or the drug should be stopped. Periodic blood level checks can help, particularly in patients with changing kidney function, new medications that might interact, or unexplained symptoms. The therapeutic range is generally considered to be between 200 and 1000 nanograms per milliliter, but toxicity has been reported even within the upper end of this range in certain patients.
Patients on flecainide should be told to report new dizziness, visual disturbances, or a feeling that their heart is racing or fluttering differently than before. They should also be aware that seemingly unrelated new medications, including over-the-counter drugs and supplements, can alter flecainide levels. And for households with young children, the medication should be stored with the same caution as any other potentially lethal drug: locked and out of reach, every time.